Heart Failure with Carfilzomib in Patients with Multiple Myeloma: A Meta-analysis of Randomized Controlled Trials

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

David Siegel, Thomas G Martin, A. Nooka et al. · Haematologica · 2013 · 344 citations · Full text

Medicine, Hematology, Pharmacology +11

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

Philippe Moreau, María‐Victoria Mateos, James R. Berenson et al. · The Lancet Oncology · 2018 · 206 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Robert F. Cornell, Bonnie Ky, Brendan M. Weiss et al. · Journal of Clinical Oncology · 2019 · 183 citations · Full text

Medicine, Hematology, Pharmacology +13